NASDAQ: VERAVera Therapeutics Inc Stock
$39.48-0.53 (-1.32%)
Updated Apr 18, 2024
VERA Price
$39.48
Fair Value Price
-$0.19
Market Cap
$2.15B
52 Week Low
$6.07
52 Week High
$50.78
P/E
-17.55x
P/B
21.14x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$95.99M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.73
Operating Cash Flow
-$92M
Beta
1.06
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VERA Overview
Vera Therapeutics, Incorporated develops treatments for patients with serious immunological diseases in the U.S. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. Known as Trucode Gene Repair, Inc. until 2020, Vera Therapeutics was incorporated in 2016 and is headquartered in Brisbane, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VERA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VERA ($39.48) is overvalued by 21,105.05% relative to our estimate of its Fair Value price of -$0.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VERA ($39.48) is not significantly undervalued (21,105.05%) relative to our estimate of its Fair Value price of -$0.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VERA due diligence checks available for Premium users.
Be the first to know about important VERA news, forecast changes, insider trades & much more!
VERA News
Valuation
VERA fair value
Fair Value of VERA stock based on Discounted Cash Flow (DCF)
Price
$39.48
Fair Value
-$0.19
Undervalued by
21,105.05%
VERA ($39.48) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VERA ($39.48) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VERA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-17.55x
Industry
15.68x
Market
41.33x
VERA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
21.14x
Industry
5.76x
VERA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VERA's financial health
Profit margin
Revenue
$0.0
Net Income
-$25.7M
Profit Margin
0%
VERA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$175.5M
Liabilities
$73.9M
Debt to equity
0.73
VERA's short-term assets ($172.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VERA's short-term assets ($172.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VERA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.1M
Investing
$18.6M
Financing
$24.8M
VERA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VERA vs Biotech Stocks
Vera Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.